{"created":"2023-05-15T14:52:12.365705+00:00","id":71282,"links":{},"metadata":{"_buckets":{"deposit":"040123ed-9c8c-462c-a182-ee77e912df1a"},"_deposit":{"created_by":1,"id":"71282","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"71282"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00071282","sets":["10:28"]},"author_link":["700786","700790","700788","700789","700784","700785","700791","700787"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2013-10-01","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background: The carbon ion radiotherapy (C-ion RT) for the prostate cancer was started in 1995 using the Heavy-Ion Medical Accelerator in Chiba (HIMAC) at the National Institute of Radiological Sciences (NIRS), Japan. After preceding phase I/II dose escalation studies of 20 fractions over 5 weeks, a phase II study was initiated in April 2000 using the treatment techniques and the recommended dose fractionation established by the phase I/II studies. This study was also successfully completed in October 2003 when the C-ion RT for the solid tumors including the prostate cancer was approved as ,Advanced Medicine, from the Ministry of Health, Labor, and Welfare. \nMaterials and methods: A phase II study of C-ion RT (9904[1]-[3]) for localized prostate cancer (T1b-T3bN0M0) was started from April 2000. A C-ion RT schedule of 66.0GyE/20fr./5weeks, 63.0GyE/20fr./5w and 57.6GyE/16fr./4w were used in 9904[1], 9904[2] and 9904[3] trials, respectively. The patients with low-risk prostate cancer were treated with C-ion RT alone, and the patients with intermediate-risk and high-risk prostate cancer were treated with C-ion RT combined with hormonal therapy of 6 months and >24 months, respectively. Biochemical failure was defined as PSA increase of 2.0ng/ml above nadir after the treatment.\nResults: A total of 1,144 patients were enrolled to the clinical study. Out of 1,144 patients, more than 50% patients were categorized as high-risk group with T3 clinical stage, Gleason,s score of 8 or higher, or PSA of 20 or higher. The 5-year overall survival rate and biochemical relapse free rate of the entire group was 95.7% and 91.0%, respectively. Biochemical relapse free rates of low-, intermediate- and high-risk patients were 90.1%, 94.2% and 89.7%, respectively. T-stage, Gleason score was significant prognostic factors for both the biochemical control and patient survival and initial PSA was also a predictive factor for survival. Regarding the late radiation toxicity, incidence of rectal toxicity of grade 2 or worse was 1.1% and that of genitourinary toxicity was 6.5%, respectively. In addition, incidence of the toxicity in the patients treated with more hypofractionated C-ion RT of 16 fractions over 4 weeks were lower than those of 20 fraction-treatment. \nConclusions: These favorable outcomes can be thought as apparent evidence of physical and biological advantages of the hypofractionated C-ion RT.","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"The 17th ECCO- 38th ESMO-  32nd ESTRO European Cancer Congress","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Nomiya, Takuma"}],"nameIdentifiers":[{"nameIdentifier":"700784","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tsuji, Hiroshi"}],"nameIdentifiers":[{"nameIdentifier":"700785","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Maruyama, Katsuya"}],"nameIdentifiers":[{"nameIdentifier":"700786","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kamada, Tadashi"}],"nameIdentifiers":[{"nameIdentifier":"700787","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"野宮 琢磨","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"700788","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"辻 比呂志","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"700789","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"丸山 克也","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"700790","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"鎌田 正","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"700791","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"Up-to-date Results of Carbon-ion Radiotherapy for Prostate Cancer: Analysis of 1,144 Patients","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Up-to-date Results of Carbon-ion Radiotherapy for Prostate Cancer: Analysis of 1,144 Patients"}]},"item_type_id":"10005","owner":"1","path":["28"],"pubdate":{"attribute_name":"公開日","attribute_value":"2013-10-10"},"publish_date":"2013-10-10","publish_status":"0","recid":"71282","relation_version_is_last":true,"title":["Up-to-date Results of Carbon-ion Radiotherapy for Prostate Cancer: Analysis of 1,144 Patients"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T19:53:03.421986+00:00"}